Dr. Susanna Lioi

Pubblications: PubMed

Operative Unit: Medical Retina Operating Unit

Sub-specialties: Age-related Macular Degeneration (AMD), Refractive Errors of the eye, Retinal Detachment, Hypovision and visual rehabilitation, Retinal Vein Occlusion, Diabetic retinopathy

Clinical activity: Dr. Susanna Lioi  since 2010 has been working for Medical Retinal Unit ‘Fondazione G.B.Bietti-IRCCS’ in clinical-scientific activities.
Mainly she works for clinical trials as Study- cordinator and Co- Investigator and her main interests concern Orthoptics , Low vision and Visual Rehabilitation and Instrumental diagnostic tests for Retinal deseases.


Education

She graduated in Orthoptics and Ophthalmological Assistance at  Rome University  ‘Tor Vergata’ in 2009 with 110/110 with Honor.

Since 2010 Researcher for Medical Retinal Unit ‘Fondazione G.B.Bietti-IRCCS, via Livenza 3, 00198, Rome

  • A Clinical Safety and Efficacy Comparison of  NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
    (MIZAR)
    Co-Investigator
  • Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema
    (RETAIN).
    Co-investigator.
  • A 12-Month, multicenter, randomized, parallel group study to compare the efficacy and safety of Ozurdex versus Lucentis in patients with branch retinal vein occlusion.
    (COMO)
    Study-coordinator
  • A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema
    (VIVID).
    study-coordinator.
  • A6-month,Phase II, Double-masked, Multicenter, Randomized,Placebo- controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice  Daily for the Treatment of Center- involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy . (FOVEA)
    Co-investigator.
  • A multicentric open-label randomized study comparing the efficacy and safety of 700  g dexamethasone segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema
    (LUZO)
    Co-investigator
  • A 12-month, phase IIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration  (TREND)
    Study-coordinator
  • A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    (MINERVA)
    Study- coordinator
  • A PHASE 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovista ( anti pdgf-b pegylated aptamer) administered in combination with Lucentis compared to lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
    (Fovista-OPH1002)
    Study-coordinator
  • A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration.
    (CHROMA)
    Study coordinator
  • A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
    (Fovista-OPH1004)
    Study coordinator
  • Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients
    With Neovascular Age-related Macular Degeneration
    (SEQUOIA)
    Co-investigator
  • An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
    (AZURE)
    Co-investigator
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized,   open-label, active-controlled, parallel-group phase IV/IIIb study
    (ARIES)
    Co-investigator
  • A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion  (CENTERA)
    Co-investigator